EDINBURGH MOLECULAR IMAGING

See. Treat. Cure.
Highly Specific Cancer Targeting
Using its proprietary platform technology, EM Imaging is developing a pipeline of highly novel in vivo c-Met targeting theragnostic and optical imaging agents that will alter the landscape of precision medicine.
Pipeline
EM Imaging has a portfolio of agents addressing a number of unmet medical needs
Ongoing Clinical Studies
EM Imaging is focused on the development of fluorescent optical imaging and therapeutic agents. Our current clinical trials are detailled in a dedicated section.
Latest Press Release
Edinburgh Molecular Imaging Closes Financing
To accelerate evelopment of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – 17 December 2019 – Edinburgh Molecular Imaging Ltd,...
Our Latest News
Results from Phase II clinical development of EMI-137 published
The work carried ou as part of Phase IIb stage of development of EMI-137 has showed FME using EMI-137 appeared to be safe andfeasible within a 1- to 3-h dose-to-imaging interval. No...
Edinburgh Molecular Imaging announce Bowel Cancer UK and Beating Bowel Cancer as charity partner
Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner. EM Imaging, based in Edinburgh, is partnering with Bowel Cancer UK and Beating Bowel Cancer...